Pharmaceuticals, Biotechnology and Life Sciences
Joseph Gunnar & Co., LLC, has exercised its over-allotment option to purchase an additional 122,500 common shares from the Akers Biosciences at $1.20 per share with the issuance of a further 61,250 warrants with an exercise price of $1.50 (the Warrants).
BioGaia has signed an exclusive agreement with Abbott for the rights to commercialize BioGaia products in the area of paediatrics and gastroenterology in Thailand.
Weifa has made a deal with New Zealand’s AFT Pharmaceuticals according to which it will sell drugs for pain relief and fever symptoms in the Nordic region (Norway, Sweden, Denmark, Finland and Iceland).
Mainstay Medical International has applied for ReActiv8 to be admitted to the Australian Register of Therapeutic Goods (ARTG) which would…
Pixium Vision, a company developing and commercializing innovative bionic vision systems, has completed 10 implants in its Iris II study.
U.S. President-elect Donald Trump on Wednesday said pharmaceutical companies are “getting away with murder” in what they charge the government for medicines, and promised that would change, sending drugs stocks sharply lower.
The Walloon (Belgium) government has decided to fund its ASIT Biotech to help develop new drug candidates to treat the main food allergies caused by peanuts, cow’s milk and egg whites.
OptiBiotix Health will have its two abstracts presented at ProBiota 2017 in Berlin, which is taking place from February 1-3, 2017. ProBiota is the leading annual event for the global prebiotic, probiotic and the microbiota focused food and pharma industries.
Two UK-based biopharma companies, Mereo BioPharma and Diurnal have reshuffled their managerial lineups by swapping managers and welcoming new people.
MaxCyte has been engaged in a study with National Institutes of Health’s (NIH) allergy and infection section to show certain CYBB gene behaviour in patients with X-linked chronic granulomatous disease (X-CGD).